Orexo Ab Stock Net Income
| ORXOF Stock | USD 3.23 0.00 0.00% |
As of the 23rd of January, Orexo AB holds the Risk Adjusted Performance of 0.1316, variance of 0.9188, and Coefficient Of Variation of 571.29. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Orexo AB, as well as the relationship between them. Put it differently, you can use this information to find out if the company will indeed mirror its model of past market data, or the prices will eventually revert. We were able to break down and interpolate data for eleven technical drivers for Orexo AB, which can be compared to its competitors. Please check Orexo AB coefficient of variation and maximum drawdown to decide if Orexo AB is priced some-what accurately, providing market reflects its current price of 3.23 per share. Given that Orexo AB has variance of 0.9188, we recommend you to check out Orexo AB's recent market performance to make sure the company can sustain itself at a future point.
Orexo AB's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Orexo AB's valuation are provided below:Orexo AB does not presently have any trending fundamental ratios for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Orexo |
Orexo AB 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Orexo AB's otc stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Orexo AB.
| 10/25/2025 |
| 01/23/2026 |
If you would invest 0.00 in Orexo AB on October 25, 2025 and sell it all today you would earn a total of 0.00 from holding Orexo AB or generate 0.0% return on investment in Orexo AB over 90 days. Orexo AB is related to or competes with Shield Therapeutics, Grown Rogue, Biosyent, Cannara Biotech, and Jushi Holdings. Orexo AB , a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the ... More
Orexo AB Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Orexo AB's otc stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Orexo AB upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | 0.0665 | |||
| Maximum Drawdown | 5.9 |
Orexo AB Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Orexo AB's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Orexo AB's standard deviation. In reality, there are many statistical measures that can use Orexo AB historical prices to predict the future Orexo AB's volatility.| Risk Adjusted Performance | 0.1316 | |||
| Jensen Alpha | 0.1476 | |||
| Total Risk Alpha | 0.0357 | |||
| Treynor Ratio | 1.46 |
Orexo AB January 23, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1316 | |||
| Market Risk Adjusted Performance | 1.47 | |||
| Mean Deviation | 0.3254 | |||
| Coefficient Of Variation | 571.29 | |||
| Standard Deviation | 0.9586 | |||
| Variance | 0.9188 | |||
| Information Ratio | 0.0665 | |||
| Jensen Alpha | 0.1476 | |||
| Total Risk Alpha | 0.0357 | |||
| Treynor Ratio | 1.46 | |||
| Maximum Drawdown | 5.9 | |||
| Skewness | 5.65 | |||
| Kurtosis | 31.0 |
Orexo AB Backtested Returns
At this point, Orexo AB is somewhat reliable. Orexo AB maintains Sharpe Ratio (i.e., Efficiency) of 0.18, which implies the firm had a 0.18 % return per unit of risk over the last 3 months. We have found sixteen technical indicators for Orexo AB, which you can use to evaluate the volatility of the company. Please check Orexo AB's Variance of 0.9188, coefficient of variation of 571.29, and Risk Adjusted Performance of 0.1316 to confirm if the risk estimate we provide is consistent with the expected return of 0.18%. Orexo AB has a performance score of 14 on a scale of 0 to 100. The company holds a Beta of 0.11, which implies not very significant fluctuations relative to the market. As returns on the market increase, Orexo AB's returns are expected to increase less than the market. However, during the bear market, the loss of holding Orexo AB is expected to be smaller as well. Orexo AB right now holds a risk of 0.98%. Please check Orexo AB coefficient of variation, maximum drawdown, as well as the relationship between the Maximum Drawdown and day typical price , to decide if Orexo AB will be following its historical price patterns.
Auto-correlation | 0.22 |
Weak predictability
Orexo AB has weak predictability. Overlapping area represents the amount of predictability between Orexo AB time series from 25th of October 2025 to 9th of December 2025 and 9th of December 2025 to 23rd of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Orexo AB price movement. The serial correlation of 0.22 indicates that over 22.0% of current Orexo AB price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.22 | |
| Spearman Rank Test | 1.0 | |
| Residual Average | 0.0 | |
| Price Variance | 0.01 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Orexo AB reported net income of (223.5 Million). This is 165.49% lower than that of the Healthcare sector and significantly lower than that of the Drug Manufacturers—Specialty & Generic industry. The net income for all United States stocks is 139.14% higher than that of the company.
Orexo Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Orexo AB's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Orexo AB could also be used in its relative valuation, which is a method of valuing Orexo AB by comparing valuation metrics of similar companies.Orexo AB is currently under evaluation in net income category among its peers.
Orexo Fundamentals
| Return On Equity | -0.65 | |||
| Return On Asset | -0.0965 | |||
| Profit Margin | (0.28) % | |||
| Current Valuation | 76.98 M | |||
| Shares Outstanding | 34.35 M | |||
| Shares Owned By Insiders | 17.29 % | |||
| Shares Owned By Institutions | 42.78 % | |||
| Price To Earning | 58.66 X | |||
| Price To Book | 2.02 X | |||
| Price To Sales | 0.99 X | |||
| Revenue | 565 M | |||
| Gross Profit | 521.7 M | |||
| EBITDA | (141.3 M) | |||
| Net Income | (223.5 M) | |||
| Cash And Equivalents | 45.61 M | |||
| Cash Per Share | 1.32 X | |||
| Total Debt | 492.3 M | |||
| Debt To Equity | 1.76 % | |||
| Current Ratio | 2.05 X | |||
| Book Value Per Share | 1.07 X | |||
| Cash Flow From Operations | (229 M) | |||
| Number Of Employees | 126 | |||
| Beta | 0.72 | |||
| Market Capitalization | 58.7 M | |||
| Total Asset | 1.27 B | |||
| Working Capital | 604 M | |||
| Current Asset | 907 M | |||
| Current Liabilities | 303 M | |||
| Net Asset | 1.27 B |
About Orexo AB Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Orexo AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Orexo AB using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Orexo AB based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Orexo OTC Stock
Orexo AB financial ratios help investors to determine whether Orexo OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Orexo with respect to the benefits of owning Orexo AB security.